Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 11/20 | 0.49 |
| ▸ | DRD2 | P14416 | 8/20 | 0.49 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6350176 | 1.00 | DRD4 (0.49) | DRD4DRD2CCR2KMT2AHTR1A | |
| SCHEMBL6360092 | 1.00 | DRD4 (0.49) | DRD4DRD2CCR2KMT2AHTR1A | |
| SCHEMBL6359415 | 0.88 | DRD2 (0.53) | DRD4DRD2 | |
| SCHEMBL6351430 | 0.88 | DRD2 (0.53) | DRD4DRD2 | |
| SCHEMBL6351433 | 0.88 | DRD2 (0.53) | DRD4DRD2 | |
| SCHEMBL6348901 | 0.84 | DRD4 (0.60) | DRD4DRD2DRD1DRD5DRD3 | |
| SCHEMBL6348903 | 0.84 | DRD4 (0.60) | DRD4DRD2DRD1DRD5DRD3 | |
| SCHEMBL6350366 | 0.84 | KMT2A (0.62) | DRD2CCR2KMT2AHTR1ADRD1 | |
| SCHEMBL6360655 | 0.82 | DRD4 (0.54) | DRD4DRD2KMT2A | |
| SCHEMBL6360652 | 0.82 | DRD4 (0.54) | DRD4DRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | claimed |
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176727-A1 | Oximes and hydrazones that are useful in treating sexual dysfunction | CYP19A1, SHBG, CYP17A1 | DRD4 1272/4885DRD2 1704/4885CCR2 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.